Rukobia (fostemsavir) was approved by the U.S. Food and Drug Administration (FDA) on February 6, 2020 [1]. This approval was for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults who have limited or no remaining options [1].
What is Rukobia used for?
Rukobia is an antiviral medication used in combination with other antiretroviral agents to treat adults with multidrug-resistant HIV-1 infection [1]. It is designed for individuals who have had their virus not suppressed on their current treatment regimen [1].
How does Rukobia work?
Rukobia is a first-in-class HIV-1 attachment inhibitor [1]. It works by preventing the HIV-1 virus from entering host cells [1]. This mechanism of action differs from many other HIV medications, making it effective against viruses that have developed resistance to other drug classes [1].
When does Rukobia's patent expire?
Information regarding the specific patent expiry dates for Rukobia is available through specialized drug patent databases. For instance, DrugPatentWatch.com tracks patent information for pharmaceutical products [2].
Who manufactures Rukobia?
ViiV Healthcare, a company focused on HIV treatment, manufactures Rukobia [1].
What are the potential side effects of Rukobia?
Common side effects reported in clinical trials for Rukobia include nausea, diarrhea, headache, and upper abdominal pain [1]. It is important for patients to discuss any potential side effects with their healthcare provider [1].